|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||74.10 - 75.73|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.60|
|Forward Dividend & Yield||2.08 (2.72%)|
|1y Target Est||N/A|
Here's why this biotech stock's single-digit earnings multiple looks more like an opportunity than a trap.
Shares of Galapagos (GLPG) ended higher Friday, after it announced it would co-promote its rheumatoid arthritis treatment filgotinib in Europe with partner Gilead Sciences (GILD), just before lock-up expired. Leerink’s Geoffrey Porges writes that this is good for filgotinib, since Galapagos is doubling down on its investment in it. Gilead will understand that its relationships to their partners and the biotech “ecosystem” are vital to its future, in our view and both would be damaged by anything other than a negotiated (generous) purchase of Galapagos.
A U.S. government reimbursement system that doesn’t fully cover the costs for Gilead Sciences Inc.’s complex blood cancer therapy is partly to blame for the slow uptake of the novel life-saving treatment, ...
Teva continued its two-day upswing Friday after announcing the launch of a generic version of a drug from Gilead, a day after the drugmaker unveiled a massive cost-cutting plan.
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.
Shares of Teva Pharmaceutical Industries Ltd. rallied 3.5% in premarket trade Friday, after the drug maker announced the exclusive launch of generic Viread 1 tablets (300 milligrams) in the U.S. The rally ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Gilead Sciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Bristol-Myers Squibb’s (BMY) virology portfolio includes hepatitis B , hepatitis C, and HIV products. The chart below compares revenue for each product category over the last few quarters. Baraclude, the ...
U.S. stock futures are trending higher this morning, as Wall Street continues to digest the Federal Reserve’s interest rate hike and accompanying policy statement. Diving right into Wednesday’s options activity, JD.com Inc(ADR) (NASDAQ:JD) attracted a spike in call volume after Stifel resumed coverage on the Chinese e-retailer. Meanwhile, Time Warner Inc. (NYSE:TWX) was also call heavy despite an ongoing lawsuit with the government over AT&T Inc.’s (NYSE:T) acquisition.
Two months after Gilead Sciences Inc.’s breakthrough treatment was approved in the U.S. to treat a deadly form of blood cancer, only a tiny handful of patients have actually gotten the costly therapy, ...
The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta. This year's meeting was ...
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Shares of Gilead Sciences (GILD) are down today, a day after rising on the company's upbeat data on its developing cancer therapy. Today, Kite, which Gilead bought earlier this year, announced updated results from the ongoing study of KTE-C19, part of its CAR-T therapy lineup aimed at patients with relapsed or refractory acute lymphoblastic leukemia. Kite said that with a minimum of eight weeks of follow-up, 71% of patients achieved complete tumor remission or complete remission with incomplete hematological recovery.
Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.